• M Vasse, Chr Denoyelle, E Guégan-Massardier, E Legrand, J-Y Borg, B Lenormand, Cl Soria, and J-P Vannier.
• Laboratoire DIFEMA-MERCI, UFR Médecine & Pharmacie de Rouen, 22, boulevard Gambetta, F76183 Rouen Cedex. marc.vasse@chu-rouen.fr
• Ann Pharm Fr. 2004 Sep 1; 62 (5): 316-22.

AbstractProtein Z (PZ) is a vitamin K dependent factor identified in human plasma in 1984 whose physiological function was poorly understood. It was recently shown that protein Z is implicated in the down-regulation of coagulation by forming a complex with a plasma proteinase inhibitor called protein Z-dependent protease inhibitor (ZPI) which inhibits activated factor Xa on phospholipid surfaces. In the absence of an additional challenge, the disruption of PZ gene in mice is asymptomatic, but the association with the factor VLeiden mutation leads to a near complete mortality during the neonatal period with microvascular thrombosis. Unexpectedly, in humans, a relationship between protein Z deficiency and ischemic strokes, was firstly evidenced, but not confirmed by all the epidemiological study. Additional studies suggest that protein Z deficiency could be also a risk factor for acute coronary syndromes, early fetal losses, and increased the arterial risk in antiphospholipid syndrome. This review analyzes the different studies so far published and discusses the different results obtained in order to understand whether or not protein Z deficiency could be considered as an arterial ischemic risk factor.

15 keywords...

hide…